Abernethy’s appointment sheds light on Verily’s plans

Verily’s hiring of Amy Abernethy, who recently stepped down as FDA’s principal deputy commissioner, sheds some light on the company’s plans for its healthcare businesses, including conducting clinical trials for itself and for life sciences companies, and developing and selling tools to make clinical research more efficient.

Verily, a subsidiary of Alphabet Inc. (NASDAQ:GOOG), was launched in 2015. Former FDA Commissioner Rob Califf is head of clinical policy and strategy at Verily. ...